June 1, 2025 – Page 7 – Marius Grobler

BRP Inc. price target raised to C$60 from C$49 at Citi

https://finance.yahoo.com/news/brp-inc-price-target-raised-124614601.html

L3Harris Technologies price target raised to $270 from $240 at TD Cowen

https://finance.yahoo.com/news/l3harris-technologies-price-target-raised-124035195.html

Unity upgraded to Buy at Jefferies on accelerating revenue growth expectations

https://finance.yahoo.com/news/unity-upgraded-buy-jefferies-accelerating-124049091.html

Dick’s Sporting Goods exec defends Foot Locker acquisition: ‘Like it or not, we make these decisions and investments for a lifetime’

Dick’s Sporting Goods announced the purchase of Foot Locker for $2.4 billion earlier this month.

Terrible News for Pfizer Stock Investors

The past three years have been challenging for Pfizer (NYSE: PFE). Revenue and earnings have moved in the wrong direction, as has the company’s share price. The stock is down by 56% since 2022. Although Pfizer has made some efforts to turn things around, they have been insufficient. And recent regulatory developments in the U.S. somewhat complicate things for the drugmaker.Here’s what investors need to know.Pfizer’s poor performance since 2022 is largely due to its coronavirus portfolio. After producing record revenue thanks to its work in this area, once the pandemic started receding, sales from Comirnaty, its COVID-19 vaccine, and Paxlovid, its therapy for the disease, started dropping off a cliff. However, Pfizer’s coronavirus franchise has remained critical to its overall financial results. In 2024, the company’s combined revenue from Paxlovid and Comirnaty was $11.1 billion.Continue readinghttps://www.fool.com/investing/2025/06/01/terrible-news-for-pfizer-stock-investors/